News/ News/ News/ Oncology/ R&D AACR: AbbVie says mid-stage trial backs navitoclax in myelofibrosis Phil Taylor AbbVie, Haematology, myelofibrosis, navitoclax, novel targeted cancer treatments, Oncology, Venclexta 0 Comment AbbVie’s BCL-2 inhibitor navitoclax has reported phase 2 results in a trial involving rare and hard-to-treat blood cancer Share X AACR: AbbVie says mid-stage trial backs navitoclax in myelofibrosis https://pharmaphorum.com/news/aacr-abbvie-says-mid-stage-trial-backs-navitoclax-in-myelofibrosis/